LLY.BA is trading 6.4% up at $33100.00 after Eli Lilly announced that Medicare Part D beneficiaries will be able to access Zepbound and Foundayo for $50 per month starting July 1, 2026.
- The Medicare GLP-1 Bridge program aims to provide expanded access and predictable low copays for obesity treatments, driving expectations for significantly higher demand.
- Analysts anticipate a substantial revenue boost from Lilly’s GLP-1 obesity portfolio due to the improved accessibility for the Medicare population.
- The stock's performance remains strong despite broader U.S. equity indices trading slightly lower today.